SEC Form 4 · accession 0001193125-26-265332

Metagenomi Therapeutics, Inc. · MGX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Jun 5, 2026

Accepted (ET)

Jun 10, 2026 · 11:21 am EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001785279

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Jun 5, 2026	S	3,737	$1.299	D	377,533	D
Common Stock^F3	holding	—	—		—	292,714	I	By Trust
Common stock^F4	holding	—	—		—	292,713	I	By Trust

No Table II lines on this filing.

F1These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
F2Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 29, 2026.
F3Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

President and Chief Executive Officer